The NIH Stroke Scale (NIHSS) was developed by the National Institute of Neurological Disorders and Stroke to provide a standardised, reproducible assessment of neurological deficit severity in acute stroke patients. Originally published in 1989, it has become the global standard for stroke severity quantification, used in clinical trials, treatment eligibility determinations (particularly for IV thrombolysis and mechanical thrombectomy), and outcome prediction. The scale consists of 15 items assessing consciousness, gaze, visual fields, facial palsy, limb motor function, ataxia, sensation, language, dysarthria, and extinction.

The Montreal Cognitive Assessment (MoCA) was developed by Dr. Ziad Nasreddine and colleagues in 1996 as a brief, sensitive screening tool specifically designed to detect mild cognitive impairment (MCI) — a stage often missed by the less sensitive MMSE. The MoCA takes approximately 10 minutes to administer and evaluates eight cognitive domains. It has been translated into over 100 languages and is now the most widely used brief cognitive screening instrument globally, endorsed by major neurology, geriatrics, and dementia societies. It was memorably referenced in public discourse when U.S. President Trump cited his "perfect score" on the test in 2020.

The Glasgow Coma Scale (GCS) was developed by Graham Teasdale and Bryan Jennett at the University of Glasgow in 1974 to provide an objective, standardised method of measuring consciousness in patients with traumatic brain injury. It quickly became the universal standard for neurological observation and is used in trauma, neurosurgery, neurology, and intensive care. The scale assesses three components: eye opening, verbal response, and motor response, with a total score ranging from 3 (deep coma or death) to 15 (fully awake). The Paediatric GCS (pGCS) modifies the verbal and motor components to account for age-appropriate responses in infants and young children.